Postgenomics of Neisseria meningitidis for vaccines development

Expert Review of Proteomics

Volumn 4, Issue 5, 2007, Pages 667-677

  Bernardini, Giulia ^a   Braconi, Daniela ^a   Martelli, Paola ^a   Santucci, Annalisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Electrophoresis; Meningococcal vaccine; Meningococcus; Outer membrane protein; Outer membrane vesicle; Proteomics

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE VESICLE VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

BACTERIAL STRAIN; BLOOD GROUP TYPING; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SCREENING; EPIDEMIC; GENETIC ANALYSIS; GENOMICS; HUMAN; IMMUNIZATION; MENINGITIS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVIEW;

GENOMICS; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PROTEOMICS;

NEISSERIA MENINGITIDIS; OAT MOSAIC VIRUS;

EID: 35448956398     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.5.667     Document Type: Review

References (87)

1. Morelli G, Malorny B, Muller K et al. Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol. Microbiol. 25(6), 1047-1064 (1997).
2. Wang JF, Caugant DA, Li X et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect. Immun. 60(12), 5267-5282 (1992).
3. Dyet K, Devoy A, McDowell R, Martin D. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 23(17-18), 2228-2230 (2005).
4. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 24, 4692-4700 (2006). •• Extensive overview of meningococcal vaccine.
5. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol. 53(Pt 9), 821-832 (2004). •• Describes the epidemiology and pathogenesis of Neisseria meningitidis.
6. Taha MK, Deghmane AE, Antignac A, Zarantonelli ML, Larribe M, Alonso JM. The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol. 10(8), 376-382 (2002).
7. Fernandez S, Arreaza L, Santiago I et al. Impact of meningococcal vaccination with combined serogroups A and C polysaccharide vaccine on carriage of Neisseria meningitidis C. J. Med. Microbiol. 52(Pt 1), 75-77 (2003).
8. Wuorimaa T, Dagan R, Vakevainen M et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184(9), 1211-1215 (2001).
9. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis. 5(1), 21-30 (2005). • Reviews the global use of meningococcal C with particular reference to the range of immunization strategies used internationally.
10. Pichichero M, Casey, J, Blatter M et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr. Infect. Dis. J. 24(1), 57-62 (2005).
11. Jodar L, La Force FM, Ceccarini C, Aguado T, Granoff DM, Meningococcal conjugate vaccine for Africa: a model for development of a new vaccines for the pooriest countries. Lancet 361(9372), 1902-1904 (2003). •• Profile of a vaccine for the prevention of epidemic meningococcal disease in sub-Saharan Africa.
12. Braun JM, Beuth J, Blackwell CC et al. Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens. Vaccine 22(7), 898-908 (2004).
13. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340(8827), 1074-1078 (1992).
14. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14(2), 67-79 (1991). • Describes outer membrane protein (OMP)-induced protection.
15. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol. 24(5), 1050-1057 (1995).
16. Perkins BA, Jonsdottir K, Briem H et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177(3), 683-691 (1998). • Describes OMP-induced protection.
17. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr. Infect. Dis. J. 23(12 Suppl.), S293-S298 (2004). • Describes OMP-induced protection and vaccination strategy in New Zealand.
18. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 359(9316), 1499-1508 (2002). •• Extensive overview of meningococcal vaccine.
19. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207 (1991). • Describes OMP-induced protection.
20. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B Meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820 (2000). • Describes possible new vaccine candidates derived from the meningococcal genome sequence by analyzing open reading frames that potentially code for surface-exposed or exported proteins.
21. Grifantini R, Bartolini E, Muzzi A et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol. 20(9), 914-921 (2002). •• The first paper describing the use of microarray techniques in identifying new vaccines candidates upon interaction with human epithelial cells.
22. Fraser CM, Eisen JA, Salzberg SL. Microbial genome sequencing. Nature 406(6797), 799-803 (2000).
23. Mora M, Donati C, Medini D, Covacci A, Rappuoli R. Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr. Opin. Microbiol. 9(5), 532-536 (2006). •• Describes the concept of pan-genomic reverse vaccinology.
24. Pizza M, Covacci A, Bartolozzi A et al. Mutants of pertussis toxin suitable for vaccine development. Science 246(4929), 487-500 (1989). • One the first papers describing vaccines developed using recombinant DNA technologies.
25. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 18(1-2), 57-67 (1999).
26. Ryan ET, Calderwood SB. Cholera vaccines. Clin. Infect. Dis. 31(2), 521-525 (2000).
27. Luft BJ, Dunn JJ, Lawson CL. Approaches toward the direct design of a vaccine against Borrelia burgdoferi. J. Infect. Dis. 185(Suppl. 1), S46-S51 (2002).
28. Mora M, Veggi D, Santini L, Pizza M, Rappuoli R, Reverse vaccinology. Drug Discov. Today 8(10), 459-464 (2003). • Review on reverse vaccinology.
29. Wizrenamm TM, Heinrichs JH, Adamou JE et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69(3), 1593-1598 (2001).
30. McMillan DJ, Baltzloff MR, Browning CL. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 22(21-22), 2783-2790 (2004).
31. Tettelin H, Masignani V, Cieslewicz MJ et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Natl Acad. Sci. USA 99(19), 12391-12396 (2002).
32. Ross BC, Czaikowski L, Hocking D et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19(30), 4135-4142 (2001).
33. Montigiani S, Falugi F, Scarselli M et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70, 368-379 (2002).
34. Fraser CM, Rappuoli R. Application of microbial genomic science to advanced therapeutics. Annu. Rev. Med. 56, 459-474 (2005).
35. Parkhill J, Achtman M, James KD et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404(6777), 502-506 (2000).
36. Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287(5459), 1809-1815 (2000).
37. Giuliani MM, Adu-Bodie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006). •• The search for a universal vaccine for serogroup B meningococcus.
38. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 377(6550), 632-635 (1995).
39. Yero CD, Pajon FR, Caballero ME et al. Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infection model. Vaccine 23(7), 932-939 (2005).
40. Yero D, Pajon R, Perez Y et al. Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine 25(28), 5175-5188 (2007).
41. Yero D, Pajon R, Caballero E et al. A novel method to screen genomic libraries that combines genomic immunization with the prime-boost strategy. FEMS Immunol. Med. Microbiol. 50(3), 430-433 (2007).
42. Walduck A, Rudel T, Meyer TF. Proteomic and gene profiling approaches to study host responses to bacterial infection. Curr. Opin. Microbiol. 7(1), 33-38 (2004). •• Overview on postgenomic technologies for studying host-pathogen interactions.
43. Rappuoli R. Pushing the limits of cellular microbiology: microarrays to study bacteria-host cell intimate contacts. Proc. Natl Acad. Sci. USA 97(25), 13467-13469 (2000).
44. Dietrich G, Kurz S, Hubner C et al. Transcriptome analysis of Neisseria meningitidis during infection. J. Bacteriol. 185(1), 155-164 (2003).
45. Kurz S, Hubner C, Aepinus C et al. Transcriptome-based antigen identification for Neisseria meningitidis. Vaccine 21(7-8), 768-775 (2003).
46. Guckenberger M, Kurz S, Aepinus C et al. Analysis of the heat shock response of Neisseria meningitidis with cDNA-and oligonucleotide-based DNA microarrays. J. Bacteriol. 184(9), 2546-2551 (2002).
47. Grifantini R, Sebastian S, Frigimelica E et al. Identification of iron-activated and repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc. Natl Acad. Sci. USA 100(16), 9542-9547 (2003).
48. Langen H, Takacs B, Evers S et al. Two-dimensional map of the proteome of Haemophilus influenzae. Electrophoresis 21(2), 411-429 (2000).
49. Kolker E, Purvine S, Galperin MY et al. Initial proteome analysis of model microorganism Haemophilus influenzae strain Rd KW20. J. Bacteriol. 185(15), 4593-4602 (2003).
50. VanBogelen RA, Abshire KZ, Moldover B, Olson ER, Neidhardt FC. Escherichia coli proteome analysis using the gene-protein database. Electrophoresis 18(8), 1243-1251 (1997).
51. Pleissner KP, Eifert T, Buettner S et al. Web-accessible proteome databases for microbial research. Proteomics 4(5), 1305-1313 (2004).
52. Bernardini G, Renzone G, Comanducci M et al. Proteome analysis of Neisseria meningitidis serogroup A. Proteomics 4(10), 2893-2926 (2004). •• The first proteomic reference map of a serogroup A Neisseria meningitidis clinical isolate.
53. Zhu P, van der Ende A, Falush D et al. Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proc. Natl Acad. Sci. USA 98(9), 5234-5239 (2001).
54. Vandahl BB, Birkelund S, Demol H et al. Proteome analysis of the Chlamydia pneumoniae elementary body. Electrophoresis 22(6), 1204-1223 (2001).
55. Mignogna G, Giorgi A, Stefanelli P et al. Inventory of the proteins in Neisseria meningitidis serogroup B strain MC58. J. Proteome Res. 4(4), 1361-1370 (2005). •• Proteomic reference map of serogroup B N. meningitidis strain MC58.
56. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20(18), 3551-3567 (1999).
57. Norais N, Nogarotto R, Lacobini ET et al. Combined automated PCR cloning, in vitro transcription/translation and two-dimensional electrophoresis for bacterial proteome analysis. Proteomics 1(11), 1378-1389 (2001).
58. Cordwell SJ. Technologies for bacterial surface proteomics. Curr. Opin. Microbiol. 9(3), 320-329 (2006).
59. Haake DA, Matsunaga J. Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins. Infect. Immun. 70(9), 4936-4945 (2002).
60. Nally JE, Whitelegge JP, Bassilian S, Blanco DR, Lovett MA. Characterization of the outer membrane proteome of Leptospira interrogans expressed during acute lethal infection. Infect. Immun. 75(2), 766-773 (2007).
61. Rosenqvist E, Hoiby EA, Wedege E. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63(12), 4642-4652 (1995).
62. Sanchez S, Arenas J, Abel A, Criado MT, Ferreiros CM. Analysis of outer membrane protein complexes and heat-modifiable proteins in Neisseria strains using two-dimensional diagonal electrophoresis. J. Proteome Res. 4(1), 91-95 (2005). •• Describes a proteomic analysis on outer membrane vesicles (OMV).
63. Molinari M, Helenius A. Analyzing cotranslational protein folding and disulfide formation by diagonal sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Methods Enzymol. 348, 35-42 (2002).
64. Post DM, Zhang D, Eastvold JS, Teghanemt A, Gibson BW, Weiss JP. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J. Biol. Chem. 280(46), 38383-38394 (2005). •• Describes a proteomic analysis on OMV.
65. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67(4), 593-656 (2003).
66. Baik SC, Kim KM, Song SM et al. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of Helicobacter pylori strain 26695. J. Bacteriol. 186(4), 949-955 (2004).
67. Molloy MP, Phadke ND, Maddock JR, Andrews PC. Two-dimensional electrophoresis and peptide mass fingerprinting of bacterial outer membrane proteins. Electrophoresis 22(9), 1686-1696 (2001).
68. Ferrari G, Garaguso I, Adu-Bobie J et al. Outer membrane vesicles from group B Neisseria meningitidis Δgna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6(6), 1856-1866 (2006). •• Describes a proteomic analysis on OMV.
69. Uli L, Castellanos-Serra L, Betancourt L et al. Outer membrane vesicles of the VAMENGOC-BC vaccine against serogroup B of Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 6(11), 3389-3399 (2006). •• Describes a proteomic analysis on OMV.
70. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 6(11), 3400-3413 (2006). •• Describes a proteomic analysis on OMV.
71. Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum. Vaccin. 1(2), 80-84 (2005).
72. Carboni L, Piubelli C, Righetti PG, Jansson B, Domenici E. Proteomic analysis of rat brain tissue: comparison of protocols for two-dimensional gel electrophoresis analysis based on different solubilizing agents. Electrophoresis 23(24), 4132-4141 (2002).
73. Vaughan TE, Skipp PJ, O'Connor CD et al. Proteomic analysis of Neisseria lactamica and Neisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine 24(25), 5277-5293 (2006). •• Describes a proteomic analysis on OMV.
74. Bos MP, Tommassen J. Biogenesis of the Gram-negative bacterial outer membrane. Curr. Opin. Microbiol. 7(6), 610-616 (2004).
75. Roe MR, Griffin TJ. Gel-free mass spectrometry-based high-throughput proteomics: tools for studying biological response of proteins and proteomes. Proteomics 6, 4678-4687 (2006). • Review on the use of gel-free strategies to make new discoveries at the proteome level.
76. Fischer F, Wolters D, Rogner M, Poetsch A. Toward the complete membrane proteome: high coverage of integral membrane proteins through transmembrane peptide detection. Mol. Cell. Proteomics 5(3), 444-453 (2006).
77. Florens L, Washburn MP, Raine JD. A proteomic view of the Plasmodium falciparum life cycle. Nature 419(6906), 520-526 (2002).
78. Doolan, DL, Southwood, S, Freilich DA et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl Acad. Sci. USA 100, 9952-9957 (2003).
79. Hardwidge PR, Donohoe S, Aebersold R, Finlay BB. Proteomic analysis of the binding partners to enteropathogenic Escherichia coli virulence proteins expressed in Saccharomyces cerevisiae. Proteomics 6, 2174-2179 (2006).
80. Goodchild A, Raftery M, Saunders NF, Guilhaus, M, Cavicchioli R. Cold adaptation of the Antarctic archaeon, Methanococcoides burtonii assessed by proteomics using ICAT. J. Proteome Res. 4, 473-480 (2005). • The first use of ICAT technology to decipher changes in protein expression during cold adaptation in Methanococcoides burtonii.
81. Ong SE, Blagoev B, Kratchmarova I et al. Stable-isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
82. Neher SB, Villen J, Oakes EC et al. Proteomic profiling of ClpXP substrates after DNA damage reveals extensive instability within SOS regulon. Mol. Cell. 22(2), 193-204 (2006).
83. Choe LH, Aggarwal K, Franck Z, Lee KH. A comparison of the consistency of proteome quantitation using two-dimensional electrophoresis and shotgun isobaric tagging in Escherichia coli cells. Electrophoresis 26(12), 2437-2449 (2005). • Examines the advantages and disadvantages of iTRAQ.
84. Chong PK, Gan CS, Pham TK, Wright PC. Isobaric tags for relative and absolute quantitation (iTRAQ) reproducibility: implication of multiple injections. J. Proteome Res., 5(5), 1232-1240 (2006).
85. Bernardini G, Arena S, Braconi D, Scaloni A, Santucci A. Novel identification of expressed genes and functional classification of hypothetical proteins from Neisseria meningitidis serogroup A. Proteomics 7(18), 3342-3347 (2007).
86. Max Planck Institute for Infection Biology www.mpiib-berlin.mpg.de
87. Scientific and Didactic Services: Neisseria Proteomics http://schubert.bio.uniroma1.it/neisseria